Rewardle Holdings Limited (ASX:RXH) Announces March Quarterly Activities Update
Rewardle Holdings (ASX:RXH) reports positive Q3 cash flow and strategic growth initiatives, including its partnership with CloudHolter.
Category: Companies
Eureka Group Holdings Limited (ASX:EGH) Secures $185 Million Debt Facility
Eureka Group Holdings Limited (ASX:EGH) secures a $185 million debt facility to support its growth and expansion plans.
Race Oncology (ASX:RAC) Announces Safe Dosing of First Patient in Phase 1 RC220 Trial
Race Oncology (ASX:RAC) successfully dosed the first patient in the Phase 1 RC220 trial for advanced solid tumours, marking a key milestone.
Baby Bunting Group Limited (ASX:BBN) Reports Sales Growth and Opens New Store
Baby Bunting Group Limited (ASX:BBN) reports a 2.9% YTD sales growth and opens a new “Store of the Future” in Melbourne, increasing FY25 NPAT guidance.
KALiNA Power Limited (ASX:KPO) Advances AI Data Centre Projects and Secures Funding
KALiNA Power Limited (ASX:KPO) reports Q1 2025 activities, advancing AI data centre projects and securing new funding.
Dimerix Limited (ASX:DXB) Secures Major Licensing Deal in Japan and FDA Endorsement for DMX-200
Dimerix Limited (ASX:DXB) secures a ¥10.5 billion licensing deal in Japan and receives FDA endorsement for its DMX-200 therapy.
Australian Gold and Copper Ltd (ASX:AGC) Accelerates Achilles Exploration Program in 2025
Australian Gold and Copper Ltd (ASX:AGC) accelerates its Achilles exploration program, reporting strong geochemical anomalies and notable drilling results in 2025.
Cobre Limited (ASX:CBE) Secures BHP Agreement and Reports Strong Exploration Results
Cobre Limited (ASX:CBE) secures a major earn-in agreement with BHP and delivers encouraging exploration results in Botswana and Australia.
BPH Global Limited (ASX:BP8) Releases Quarterly Activities Report and Secures Funding
BPH Global Limited (ASX:BP8) releases Q1 2025 report, secures $609K funding, and advances Indonesian seaweed projects.
ImpediMed Limited (ASX:IPD) Announces Q3 Revenue and ARR Growth
ImpediMed Limited (ASX:IPD) reports record Q3 revenue and ARR growth, along with key operational and management developments.